WilmerHale Represents Generation Bio in $100M Series B Financing

• 2.28.2018

Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, recently announced the closing of a $100 million Series B financing. Proceeds will be used to move Generation Bio's first two therapeutic candidates through Investigational New Drug enabling studies and to advance additional programs targeting genetic diseases of the retina, central nervous system and lungs. This follows on the heels of the company's previously announced $25 million Series A financing.

The WilmerHale team representing Generation Bio includes Stuart Falber, Stephanie Singer and Brett Bromann, with licensing counsel from Steve Barrett.

Read the press release announcing this news for more information.